Nuvectis Pharma
Update in progressNVCT (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for serious oncology conditions with unmet medical need. Its lead candidate, NXP900, is a small molecule in Phase 1b that inhibits the c-Src and YES1 kinases to target solid tumors. The company, formerly Centry Pharma, changed its name in July 2021. It was incorporated in 2020 and is based in Fort Lee, New Jersey.
Company score
- Sentiment
- 0.00
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.11
- Governance
- 0.12
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.01
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.01
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!